NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

Galectin Therapeutics logo
$2.69 -0.12 (-4.27%)
As of 11/20/2026 03:57 PM Eastern

About Galectin Therapeutics Stock (NASDAQ:GALT)

Advanced

Key Stats

Today's Range
$2.67
▼
$2.93
50-Day Range
$2.69
▼
$4.14
52-Week Range
$2.03
▼
$7.13
Volume
257,651 shs
Average Volume
203,072 shs
Market Capitalization
$177.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Hold

Company Overview

Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer.

Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.

The company was previously known as Pro-Pharmaceuticals before adopting the Galectin Therapeutics name. Its work is centered on drug research and clinical development rather than the sale of marketed medicines.

AI Generated. May Contain Errors.

Galectin Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

GALT MarketRank™: 
1.785513756315 of 5 stars

Galectin Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 668th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Galectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Galectin Therapeutics has a consensus price target of $11.00, representing about 308.9% upside from its current price of $2.69.

  • Amount of Analyst Coverage

    Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Galectin Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Galectin Therapeutics are expected to grow in the coming year, from ($0.26) to ($0.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galectin Therapeutics is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galectin Therapeutics is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    29.00% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 46.26, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently decreased by 1.69%, indicating that investor sentiment is improving.
  • Dividend Yield

    Galectin Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Galectin Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Galectin Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Galectin Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    53.00% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    11.68% of the stock of Galectin Therapeutics is held by institutions.

  • Read more about Galectin Therapeutics' insider trading history.
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GALT Stock News Headlines

HC Wainwright Has Bullish Estimate for GALT FY2026 Earnings
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Galectin Therapeutics Inc GALT
See More Headlines

GALT Stock Analysis - Frequently Asked Questions

Galectin Therapeutics' stock was trading at $4.16 at the beginning of the year. Since then, GALT stock has decreased by 35.3% and is now trading at $2.69.

Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01.

Top institutional investors of Galectin Therapeutics include State Street Corp (1.22%), Marshall Wace LLP (0.71%), Commonwealth Equity Services LLC (0.70%) and Goldman Sachs Group Inc. (0.21%). Insiders that own company stock include James C Czirr, Fund LP 10X, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Jack W Callicutt, Harold H Shlevin and Khurram Jamil.
View institutional ownership trends
.

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Viking Therapeutics (VKTX), Walt Disney (DIS), Pfizer (PFE), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Ford Motor (F).

Company Calendar

Last Earnings
11/16/2026
Today
11/22/2026
AGM 2026
12/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GALT
CIK
1133416
Employees
9
Year Founded
2001

Price Target and Rating

High Price Target
$11.00
Low Price Target
$11.00
Potential Upside/Downside
+308.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-146.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.28
Quick Ratio
0.10

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.54) per share
Price / Book
-4.98

Miscellaneous

Outstanding Shares
65,860,000
Free Float
30,953,000
Market Cap
$177.16 million
Optionable
Optionable
Beta
0.53

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:GALT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners